At 2 years, a next-generation, low-dose paclitaxel drug-coated balloon (DCB) continues to show good safety and efficacy compared with a standard high-dose paclitaxel DCB in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results